Clinical trials: Osteoporosis Postmenopausal
Osteoporosis, Postmenopausal, Physical Activity
Efficacy and Safety of the Physical Activity Program in Women With Post-menopausal Osteoporosis
The study will be single blinded since professionals who will evaluate patients will not know to which exercise group patients have been assigned.
- Trial name
- ACTLIFE (NCT04179903)
- Testing
- Physical activity
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Istituto Ortopedico Rizzoli
Osteoporosis
Denosumab Adherence Preference Satisfaction Study
The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12…
- Trial name
- NCT00518531
- Testing
- alendronate, denosumab
- Volunteers
- 250 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis
- Trial name
- FRAME (NCT01575834)
- Testing
- Romosozumab, Denosumab
- Where
- 218 sites in United States, Argentina and 22 more
- Volunteers
- 7,180 people
- Sponsor
- Amgen
Osteoporosis
To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women.
- Trial name
- NCT00651534
- Testing
- Ronacaleret
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.
The first purpose of this study is to determine if taking SB-751689 along with Rosuvastatin (CRESTOR) or Atorvastatin (LIPITOR) will change how Rosuvastatin or Atorvastatin are absorbed and eliminated from the body.
- Trial name
- NCT00388596
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton
There are over 10 million individuals with asthma using inhaled glucocorticoids (IGCs) in the United States. While oral GCs are recognized to have destructive skeletal effects, far less is known about the effects of IGCs.
- Trial name
- NCT02357277
- Testing
- Budesonide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Columbia University
Perimenopausal Bone Loss
Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate…
- Trial name
- NCT00221312
- Testing
- Fosamax
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Osteoporosis
A Study for Patients With Osteoporosis
The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis
- Trial name
- NCT00414973
- Testing
- Teriparatide, Salmon Calcitonin
- Where
- 5 sites in China
- Volunteers
- 364 people
- Sponsor
- Eli Lilly and Company
Osteopenia or Osteoporosis
Effect of Consumption of Supplements and Enriched Olive Paste on Bone Metabolism Indices
It was a prospective randomized controlled trial. A sample of 115 apparently healthy post-menopausal women(45 -75 years of age) randomized into four groups and received supplements of Ca, Vitamin D and Mg with or without enriched…
- Trial name
- Osteoporosis (NCT06135831)
- Testing
- Functional olive paste, Calciovitmag (CDCaMg), Phosporovitmag (PDCaMg)
- Where
- Greece
- Volunteers
- 115 people
- Sponsor
- University of the Aegean
Postmenopausal Osteoporosis, Osteoporosis
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However, prolonged PTH treatment increases bone formation less and less over time.
- Trial name
- NCT00086619
- Testing
- synthetic hPTH 1-34
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk
- Trial name
- NCT07028320
- Testing
- SAL056 (56.5μg), Alendronate
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Low Bone Mass, Osteoporosis, Postmenopausal
DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women
To determine whether the musculoskeletal adaptations to bone-loading exercise can be significantly augmented in older women (aged 60-85) with low bone mass (osteopenia; T-scores <-1.0 and >-2.5) or moderate osteoporosis (T-scores…
- Trial name
- NCT03227458
- Testing
- DHEA, Exercise
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Osteoporosis
A Study of SB751689 in Japanese Postmenopausal Women
To investigate the safety and tolerability, PK and PD of SB751689 following single and 5-day multiple oral doses of 100, 200, and 400 mg in Japanese postmenopausal subjects.
- Trial name
- NCT00554255
- Testing
- SB751689
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis, Multiple Myeloma
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in…
- Trial name
- NCT05775094
- Testing
- Romosozumab
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Post-menopausal Osteoporosis
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
- Trial name
- NCT00718861
- Testing
- Zoledronic acid
- Where
- 57 sites in United States, Argentina and 16 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide.
- Trial name
- DATA-HD (NCT02176382)
- Testing
- denosumab, teriparatide, Zoledronic acid
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Post Menopausal Osteoporosis
SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
This 2 arm study will assess the impact of bone marker feedback, using blood sampling and communication of results at week 5, on persistence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis.
- Trial name
- NCT00545480
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 190 sites in France
- Volunteers
- 596 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal, Osteoporosis, Osteopenia
Effects of Physical Exercise to Prevent Osteoporosis in Postmenopausal Women
According to the World Health Organization criteria, osteoporosis was defined as a bone mineral density that lies 2.5 standard deviations or more below the average value for young healthy women.
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis, Osteopenia, Physical Activity
- Trial name
- Osteo_women (NCT03091088)
- Testing
- walking at an intense pace, osteoporosis specific-oriented training
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Valencia
Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode.
- Trial name
- OsteoNAFLD (NCT05493761)
- Testing
- Denosumab, Alendronate Sodium
- Where
- 3 sites in Greece
- Volunteers
- 72 people
- Sponsor
- Aristotle University Of Thessaloniki
Hearing Loss, Osteoporosis, Postmenopausal
Hearing Loss and Osteoporosis
To compare the audiological profiles in postmenopausal women with and without osteoporosis and to examine the pattern of hearing loss in osteoporotic patients.
- Trial name
- NCT03895333
- Testing
- Audiological profiling and bone mineral densitometry measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital